You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Warning for Renin Inhibitor Aliskiren

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000415953.54556.5e
Drug Watch

* The antihypertensive drug aliskiren (Tekturna) and products containing this drug shouldn't be coadministered with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers if the patient has diabetes or renal impairment.

* Clinical trial data indicated that there were increased risks of renal impairment, hypotension, and hyperkalemia when these combinations were used in the treatment of patients with diabetes and renal insufficiency.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2012 Lippincott Williams & Wilkins, Inc.